nodes	percent_of_prediction	percent_of_DWPC	metapath
Risperidone—HTR1D—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0251	0.0251	CbGpPWpGaD
Risperidone—HTR1B—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0246	0.0246	CbGpPWpGaD
Risperidone—ABCB1—Allograft Rejection—CXCL11—nasal cavity cancer	0.0244	0.0244	CbGpPWpGaD
Risperidone—DRD4—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0242	0.0242	CbGpPWpGaD
Risperidone—DRD3—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0215	0.0215	CbGpPWpGaD
Risperidone—HTR7—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0201	0.0201	CbGpPWpGaD
Risperidone—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.02	0.02	CbGpPWpGaD
Risperidone—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0196	0.0196	CbGpPWpGaD
Risperidone—ADRA2B—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0194	0.0194	CbGpPWpGaD
Risperidone—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0193	0.0193	CbGpPWpGaD
Risperidone—HTR1A—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0187	0.0187	CbGpPWpGaD
Risperidone—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0184	0.0184	CbGpPWpGaD
Risperidone—ADRA2C—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0181	0.0181	CbGpPWpGaD
Risperidone—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0173	0.0173	CbGpPWpGaD
Risperidone—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0171	0.0171	CbGpPWpGaD
Risperidone—DRD2—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0165	0.0165	CbGpPWpGaD
Risperidone—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0154	0.0154	CbGpPWpGaD
Risperidone—HTR7—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0153	0.0153	CbGpPWpGaD
Risperidone—HTR1D—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0152	0.0152	CbGpPWpGaD
Risperidone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0149	0.0149	CbGpPWpGaD
Risperidone—HTR1B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0149	0.0149	CbGpPWpGaD
Risperidone—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0148	0.0148	CbGpPWpGaD
Risperidone—ADRA2A—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0147	0.0147	CbGpPWpGaD
Risperidone—DRD4—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0147	0.0147	CbGpPWpGaD
Risperidone—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0144	0.0144	CbGpPWpGaD
Risperidone—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0142	0.0142	CbGpPWpGaD
Risperidone—HTR2B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.014	0.014	CbGpPWpGaD
Risperidone—DRD1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0132	0.0132	CbGpPWpGaD
Risperidone—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0131	0.0131	CbGpPWpGaD
Risperidone—DRD3—GPCR ligand binding—CXCL11—nasal cavity cancer	0.013	0.013	CbGpPWpGaD
Risperidone—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0129	0.0129	CbGpPWpGaD
Risperidone—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0129	0.0129	CbGpPWpGaD
Risperidone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0126	0.0126	CbGpPWpGaD
Risperidone—ADRA2B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0118	0.0118	CbGpPWpGaD
Risperidone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0117	0.0117	CbGpPWpGaD
Risperidone—HTR1A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0114	0.0114	CbGpPWpGaD
Risperidone—HTR2C—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0113	0.0113	CbGpPWpGaD
Risperidone—ADRA2C—GPCR ligand binding—CXCL11—nasal cavity cancer	0.011	0.011	CbGpPWpGaD
Risperidone—ADRA1B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0108	0.0108	CbGpPWpGaD
Risperidone—DRD2—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00997	0.00997	CbGpPWpGaD
Risperidone—HTR2A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00981	0.00981	CbGpPWpGaD
Risperidone—HRH1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00979	0.00979	CbGpPWpGaD
Risperidone—ADRA1A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0096	0.0096	CbGpPWpGaD
Risperidone—ADRA2A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00892	0.00892	CbGpPWpGaD
Risperidone—HTR7—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00866	0.00866	CbGpPWpGaD
Risperidone—HTR1D—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0086	0.0086	CbGpPWpGaD
Risperidone—HTR1B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00842	0.00842	CbGpPWpGaD
Risperidone—DRD4—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00829	0.00829	CbGpPWpGaD
Risperidone—HTR2B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00791	0.00791	CbGpPWpGaD
Risperidone—HTR7—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00786	0.00786	CbGpPWpGaD
Risperidone—HTR1D—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00781	0.00781	CbGpPWpGaD
Risperidone—HTR1B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00765	0.00765	CbGpPWpGaD
Risperidone—DRD4—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00753	0.00753	CbGpPWpGaD
Risperidone—DRD1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00746	0.00746	CbGpPWpGaD
Risperidone—DRD3—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00736	0.00736	CbGpPWpGaD
Risperidone—HTR2B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00718	0.00718	CbGpPWpGaD
Risperidone—DRD1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00677	0.00677	CbGpPWpGaD
Risperidone—DRD3—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00668	0.00668	CbGpPWpGaD
Risperidone—ADRA2B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00665	0.00665	CbGpPWpGaD
Risperidone—HTR1A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00642	0.00642	CbGpPWpGaD
Risperidone—HTR2C—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00638	0.00638	CbGpPWpGaD
Risperidone—ADRA2C—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00621	0.00621	CbGpPWpGaD
Risperidone—ADRA1B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00611	0.00611	CbGpPWpGaD
Risperidone—ADRA2B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00603	0.00603	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00583	0.00583	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0058	0.0058	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00564	0.00564	CbGpPWpGaD
Risperidone—DRD2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00563	0.00563	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00555	0.00555	CbGpPWpGaD
Risperidone—HTR2A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00554	0.00554	CbGpPWpGaD
Risperidone—HRH1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00553	0.00553	CbGpPWpGaD
Risperidone—ADRA1A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00543	0.00543	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00512	0.00512	CbGpPWpGaD
Risperidone—ADRA2A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00504	0.00504	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00503	0.00503	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00502	0.00502	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00493	0.00493	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—CXCL11—nasal cavity cancer	0.00464	0.00464	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—CXCL11—nasal cavity cancer	0.00461	0.00461	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00458	0.00458	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00452	0.00452	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—CXCL11—nasal cavity cancer	0.00445	0.00445	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00424	0.00424	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—CXCL11—nasal cavity cancer	0.004	0.004	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00395	0.00395	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00357	0.00357	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00344	0.00344	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—CXCL11—nasal cavity cancer	0.00342	0.00342	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—CXCL11—nasal cavity cancer	0.00333	0.00333	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00328	0.00328	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00302	0.00302	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00297	0.00297	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00297	0.00297	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00291	0.00291	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—FRS2—nasal cavity cancer	0.00274	0.00274	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—FRS2—nasal cavity cancer	0.00272	0.00272	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CXCL11—nasal cavity cancer	0.0027	0.0027	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—FRS2—nasal cavity cancer	0.00266	0.00266	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—FRS2—nasal cavity cancer	0.00262	0.00262	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—FRS2—nasal cavity cancer	0.0025	0.0025	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—FRS2—nasal cavity cancer	0.00236	0.00236	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—FRS2—nasal cavity cancer	0.00233	0.00233	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—FRS2—nasal cavity cancer	0.0021	0.0021	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—FRS2—nasal cavity cancer	0.00203	0.00203	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—FRS2—nasal cavity cancer	0.00202	0.00202	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—FRS2—nasal cavity cancer	0.00196	0.00196	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—FRS2—nasal cavity cancer	0.00193	0.00193	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—FRS2—nasal cavity cancer	0.00178	0.00178	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—FRS2—nasal cavity cancer	0.00175	0.00175	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—FRS2—nasal cavity cancer	0.00175	0.00175	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—FRS2—nasal cavity cancer	0.00172	0.00172	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—FRS2—nasal cavity cancer	0.00159	0.00159	CbGpPWpGaD
